Galectin-3和Cytokeratin-19在桥本甲状腺炎并发微小乳头状癌中不同区域的表达
|
摘要
【目的】探讨Gal-3和CK-19在桥本甲状腺炎并微小乳头状癌中不同区域的表达情况及其临床意义。
【方法】将临床收集的标本按照病理学诊断,分为桥本甲状腺炎并结节,微小乳头状癌和桥本甲状腺炎并微小乳头状癌三组；采用免疫组织化学法检测对照组A：25例桥本甲状腺炎合并发良性结节的组织(瘤组织,距瘤组织0.5CM的甲状腺组织,对侧叶),对照组B：25例微小乳头状甲状腺癌的组织(癌组织,距癌组织0.5CM的甲状腺组织,对侧叶)实验组：25例桥本氏病并微小乳头状癌的组织(癌组织,距癌组织0.5CM的甲状腺组织,对侧叶)中Gal-3和CK-19的表达。
【结果】本研究结果表明,正常甲状腺组织中Galectin-3和CK-19表达很低；对照A组其距肿瘤0.5cm处表达Galectin-3阳性率为52%(13/25),CK-19为44%(11/25)显著高于对照B组0.5cm区域(P<0.05)。实验组中距肿瘤0.5cm区域Galectin-3阳性率76%(19/25),CK-19为68%(17/25)明显高于对照A、B两组组,与对照B组行统计学分析其差异有统计学意义(P<0.05),但与对照A组行统计学分析其差异无统计学意义(P>0.05)。对照A组距肿瘤0.5cm区域Galectin-3、CK-19阳性表达：弱阳性分别为69.23%(9/13)、72.73%(8/11)；中阳性分别为23.08%(3/13)、18.18%(2/11),强阳性分别为7.69%(1/13)、9.09%(1/11)；而在实验组距肿瘤0.5cm区域中,Galectin-3、CK-19阳性表达：弱阳性分别为36.84%(7/19)、29.41%(5/17)；中阳性分别为36.84%(7/19)、47.06%(8/17),强阳性分别为26.32%(5/19)、23.53%(4/17)；对两组中阳性和强阳性分别比较其差异有统计学意义(P值均<0.05)。
【结论】
1. Galectin-3和Cytokeratin-19的联合检测可作为鉴别甲状腺良恶性肿瘤指征。
2.桥本甲状腺炎中Galectin-3和Cytokeratin-19的表达水平明显高于正常甲状腺组织中的表达情况,提示在一定程度上桥本甲状腺炎增加了癌变可能。
3. Galectin-3、CK-19联合检测有助于桥本甲状腺炎恶性变倾向的判断和甲状腺癌的早期诊断,特别在其强阳性表达中应视为已恶变。
4.桥本甲状腺炎合并微小乳头状癌时,应行手术治疗,而且应扩大手术范围,行侧叶加对侧叶大部分切除或全叶切除为宜。
[Objective] To detect the expression of galectin-3 and cytokeratin-19 in different area of Hashimoto thyroiditis with thyroid papillary microcarcinoma
[Methods] Immunohistochemical methods used to examine expression of galectin-3 and cytokeratin-19 in the area of tumor,0.5cm near the tumor and other lobec thyroid in 25 Hashimoto thyroiditis patients,25 thyroid papillary microcarcinoma patents,25 Hashimoto thyroiditis with thyroid papillary microcarcinoma patients
[Results] the research results indicated,the lower expression of galectin-3 and cytokeratin-19 in normal thyroid,s tissue;The positive rate of Galectin-3 and CK-19 in the area of 0.5cm near the tumor of the contrast group A were 52%(13/25)and 44 %(11/25) which were superior than what in the contrast group B(P<0.05);but indicated no difference between the contrast group A(P>0.05); The positive rate of Galectin-3 and CK-19 in the area of 0.5cm near the tumor of the contrast group A were Weak positive 69.23%(9/13),72.73%(8/11).positive 23.08%(3/13),18.18 %(2/11)and Strong positive 7.69%(1/13),9.09%(1/11) matched along with Weak positive 36.84%(7/19),29.41%(5/17); positive 36.84%(7/19),47.06% (8/17)and Strong positive 26.32%(5/19),23.53%(4/17)in the test group; the positive and strong positive groups showed evidently difference(P<0.05).
[Conclusion]
1.Galetin-3 protein assay combined with CK-19 are helpful to differentiate the benign thyroid tumor and malignant one.
2.The expression of Galectin-3 and Cytokeratin-19 protein in Hashimoto thyroiditis is clear higher than what in normal thyroid tissue,it is means that prognosis evalution in Hashimoto thyroiditis canceration. 3.Galectin-3 protein assay combined with CK-19 are useful in early diagnosis, the pathogenesis and prognosis evaluation thyroid cancer. When they are strong positive mean it is cancer.
4.In Hashimoto thyroiditis with thyroid papillary microcarcinoma,it need a operation therapy, and need a larger one,maybe one total and the other one subtotal or both total.
【方法】将临床收集的标本按照病理学诊断,分为桥本甲状腺炎并结节,微小乳头状癌和桥本甲状腺炎并微小乳头状癌三组；采用免疫组织化学法检测对照组A：25例桥本甲状腺炎合并发良性结节的组织(瘤组织,距瘤组织0.5CM的甲状腺组织,对侧叶),对照组B：25例微小乳头状甲状腺癌的组织(癌组织,距癌组织0.5CM的甲状腺组织,对侧叶)实验组：25例桥本氏病并微小乳头状癌的组织(癌组织,距癌组织0.5CM的甲状腺组织,对侧叶)中Gal-3和CK-19的表达。
【结果】本研究结果表明,正常甲状腺组织中Galectin-3和CK-19表达很低；对照A组其距肿瘤0.5cm处表达Galectin-3阳性率为52%(13/25),CK-19为44%(11/25)显著高于对照B组0.5cm区域(P<0.05)。实验组中距肿瘤0.5cm区域Galectin-3阳性率76%(19/25),CK-19为68%(17/25)明显高于对照A、B两组组,与对照B组行统计学分析其差异有统计学意义(P<0.05),但与对照A组行统计学分析其差异无统计学意义(P>0.05)。对照A组距肿瘤0.5cm区域Galectin-3、CK-19阳性表达：弱阳性分别为69.23%(9/13)、72.73%(8/11)；中阳性分别为23.08%(3/13)、18.18%(2/11),强阳性分别为7.69%(1/13)、9.09%(1/11)；而在实验组距肿瘤0.5cm区域中,Galectin-3、CK-19阳性表达：弱阳性分别为36.84%(7/19)、29.41%(5/17)；中阳性分别为36.84%(7/19)、47.06%(8/17),强阳性分别为26.32%(5/19)、23.53%(4/17)；对两组中阳性和强阳性分别比较其差异有统计学意义(P值均<0.05)。
【结论】
1. Galectin-3和Cytokeratin-19的联合检测可作为鉴别甲状腺良恶性肿瘤指征。
2.桥本甲状腺炎中Galectin-3和Cytokeratin-19的表达水平明显高于正常甲状腺组织中的表达情况,提示在一定程度上桥本甲状腺炎增加了癌变可能。
3. Galectin-3、CK-19联合检测有助于桥本甲状腺炎恶性变倾向的判断和甲状腺癌的早期诊断,特别在其强阳性表达中应视为已恶变。
4.桥本甲状腺炎合并微小乳头状癌时,应行手术治疗,而且应扩大手术范围,行侧叶加对侧叶大部分切除或全叶切除为宜。
[Objective] To detect the expression of galectin-3 and cytokeratin-19 in different area of Hashimoto thyroiditis with thyroid papillary microcarcinoma
[Methods] Immunohistochemical methods used to examine expression of galectin-3 and cytokeratin-19 in the area of tumor,0.5cm near the tumor and other lobec thyroid in 25 Hashimoto thyroiditis patients,25 thyroid papillary microcarcinoma patents,25 Hashimoto thyroiditis with thyroid papillary microcarcinoma patients
[Results] the research results indicated,the lower expression of galectin-3 and cytokeratin-19 in normal thyroid,s tissue;The positive rate of Galectin-3 and CK-19 in the area of 0.5cm near the tumor of the contrast group A were 52%(13/25)and 44 %(11/25) which were superior than what in the contrast group B(P<0.05);but indicated no difference between the contrast group A(P>0.05); The positive rate of Galectin-3 and CK-19 in the area of 0.5cm near the tumor of the contrast group A were Weak positive 69.23%(9/13),72.73%(8/11).positive 23.08%(3/13),18.18 %(2/11)and Strong positive 7.69%(1/13),9.09%(1/11) matched along with Weak positive 36.84%(7/19),29.41%(5/17); positive 36.84%(7/19),47.06% (8/17)and Strong positive 26.32%(5/19),23.53%(4/17)in the test group; the positive and strong positive groups showed evidently difference(P<0.05).
[Conclusion]
1.Galetin-3 protein assay combined with CK-19 are helpful to differentiate the benign thyroid tumor and malignant one.
2.The expression of Galectin-3 and Cytokeratin-19 protein in Hashimoto thyroiditis is clear higher than what in normal thyroid tissue,it is means that prognosis evalution in Hashimoto thyroiditis canceration. 3.Galectin-3 protein assay combined with CK-19 are useful in early diagnosis, the pathogenesis and prognosis evaluation thyroid cancer. When they are strong positive mean it is cancer.
4.In Hashimoto thyroiditis with thyroid papillary microcarcinoma,it need a operation therapy, and need a larger one,maybe one total and the other one subtotal or both total.
引文
[1]Lindsay S, Dailey ME, Eriedlender J, et al. Chronic throiditis:a clinical and
pathologic study of 354 patients. [J] Clin Endoerinal,1952,12(4):1578-1583.
[2]Cipolla C, Sandonato L, Graceffa G, Hashimoto thyroiditis coexistent with
papillary thyroid carcinoma[J]. Am Surg,2005,71(10):874-878[3]王兰,潘丹.桥本甲状腺炎伴甲状腺癌临床病理分析[J].临床与实验病理学杂志,2003,29(3)：286-289.
[4]Di Pasquale M, Rotjstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carCinoma[J]. Hum Pathol,2001,32 (1); 24-30.
[5]Prasad ML, Huang Y, Pellegate NS, Hashimoto's thyrioditis with papilly thyroid carcinoma(PTC)-like muclear alterations express molecular of PTC[J]. Histopathology,2004,45(1):39-46.
[6]Kim KH, Suh KS, Kang DW, Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyrioditis[J]. Pathol Int,2005,55 (9):540-545.
[7]Intidhar Labidi S, Chaabouni AM, Kraiern T, et al. Thyroid carcinoma and Hashimoto thyroiditis [J].Ann Otolaryngol Chir Cervicofac,2006,123(4):175.
[8]Costanzo M, Caruso LA, Teatar R, et al.Hashimoto thyrioitis possible cause or consequence of a malignant thyroid tumor[J]. Ann Ital Chir,2006,77(6):469.
[9]Arif S. Blanes A. Diaz-Cano SJ. Hashimot*s thyroiditis shares features with early papillaD thyroid dcarcinoma[J]. Histolmthology 2002,41(4):357-62.
[10]Honjo Y, Inohara H, Akahani S, et al. Expression of cyto-plasmic galectin-3 as a prognostic marker in tongue carcinoma[J]. Clin Cancer Res,2000,6(12): 4635-4640.
[11]Xu XC. El-Nagger AK、lotan R. differential expression of galectin-1 and galectin-3 in thyroid tumors:potential diagnostic implications[J]. Am J Puthol.1995,147(3) 815-822.
[12]Rhoden KJ, Unger K, Salvatore G, RET/papillary thyroid cancerr rearrangement in nonneoplastic thyrocytes:follicular cells of Hashimoto's thyrioditis share low-level recombination events with a subset of papillary carcinoma[J]. Clin Endocrinol Metab,2006,91 (6):2040-2042.
[13]Nikiforova M, Caudill C, Biddinger P, et al. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinoma. [J]. Int J Surg Pathol,2002,10(1):15-22.
[14]Unger P, Ewart M, Wang BY, Expression of p63 in papillary thyriod carcinoma and in Hashimoto's thyrioditis:a pathobiologic link [J]. Hum Pathol,2003,34(8):764-769.
[15]徐少明,王平等,桥本氏病并发甲状腺癌的临床分析[J].中华医学杂志,2000,80(4)：278-279.
[16]Gasbarri A, Sciacchitano S, Marasco A, Detectionand molecular characterization of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyrioditis[J].Br J Cancer,2004,91(6):1096-1104.
[17]Bartolazzi A, Gasbarri A. Papotti M, et al. Application of an Imuuodiagnostic method for improving preoperative diagnosis of nodular thyriod lesion
[J]. lancer.2001.357(9269):1664-1650.
[18]王兰,潘丹等,桥本氏甲状腺炎伴甲状腺癌的临床病理分析[J].临床与实验病理学杂志.2003 19(3)：286-289.
[19]Rosai J, Zampi G. Papillary carcinoma of the thy. mid, a discussion of its several morphologic expressions, thpanicukr emphasis on the follicular variant [J]. Am J Surg Pathol,1983,7:809-817.
[20]Sahoo S, Hoda S A, Rosai J. Cytokeratin 19 immunoreactivity in the diagnosis
of papillary thyroid carcinoma:a note of caution [J]. Am J Cl in Pathol,2001,116: 696-702.
[21]Metfinen M. Keratin subsets in papillary and fol. licular thyroid lesions:A pammn section analysis with diagnosis implications[J]. Vichows Arch,1997,431: 407.
[22]贾万钧郭艳, CK19、 galectin-3、 HBME-1和Ret蛋白在甲状腺乳头状癌中的表达[J]浙江临床医学2007 11(9)：1143-1144.
[23]王仪,魏霖等,Galectin-3、 CK19和MC在甲状腺良、恶性肿瘤中的表达及意义[J]海峡药学2007 19(12)：108-110.
[24]Kazantseva IA, Fedosenko AK, Gurevich LE, et al. Immunohistochemicalstudy in differential diagnosis of benign and malignant lesions of the thyroid gland[J]. Arkh Patol,2001,63(4):18-21.
[25]王家耀.桥本甲状腺炎与甲状腺癌的关系[J].诊断病理学杂志,1997；4(2)：106-107.
[26]戴军,陈方荟,包建东,等.桥本甲状腺炎癌变与甲状腺乳头状癌相关性分析[J].诊断病理学杂志.2005,12(6)：458-459.
[27]Di Pasquale M, Rothstein, Palazzo JP. Pathologic features of hashimoto' sassociated papillary thyroid carcinomas[J]. Hum Pathol,2001,32(1):24-30.
[28].Dayan CM, Danniels GH. Chronic autoimmune thyroiditis. New Engl [J] Med,1996;335(2):99-110.
[29]Vanderpump MPJ, Tumbridge WMC, French JM, et al. The incidence of thyroiditis:the great mimic. Nucl Med Commun;1988; 9(9):639-645.
[30]Crile G Jr. Controversies in thyroid surgery. N Y Stste J Med.1980 Nov; 80 (12) 1832-1835
[31]Martin HE, Ellis EB. Biopsy by needle puncture and aspiration. Ann surg,1930, (92):169-181.
[32]Cattell RB. Postoperation complications of thyroid surgery. Surg Clin North AM.1953 Jun:867-877.
[33]Foot NC, Baker LE, Carrel A. The behavior of abnormal human thyroid tissue cultivated in the Lindbergh apparatus. J Exp med.1939 Jun 30:70(1)39-52.
[34].李里等,桥本病合并甲状腺肿瘤的外科治疗和临床特征分析[J]中国癌症杂志.2009，19(7)：544-547.
[1]Lindsay S, Dailey ME, Eriedlender J, et al. Chronic throiditis:a clinical and pathologic study of 354 patients[J]. Clin Endoerinal,1952,12(4):1 578-1 583.
[2]顾学文,张真稳等Galectin-3、 Cytokeratin-19在甲状腺良恶性乳头状病变中的表达及临床意义[J].实用医学杂志,2005 21(12)：1125-1126.
[3]郑璐滢,朱建善等Galectin-3、 CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J]临床与实验病理学杂志[J]. Clin Exp Pathol.2005 Aug; 20(4):449-452.
[4]Honjo Y, Inohara H, Akahani S, et al. Expression of cyto-plasmic galectin-3 as a prognostic marker in tongue carcinoma[J].Clin Cancer Res,2000,6(12): 4635-4640.
[5]Ohannesian DW, Lotan D, Thomas, et al. Carcinoembryonic antigen and other glycoconiugates act as ligands for galeetin-3 in human colon carcinoma cells [J]. Cancer Res,1995,55(10):2191-2199.
[6]Xu XC, El-Nagger AK, lotan R. differential expression of galectin-1 and galectin-3 in thyroid tumors:potential diagnostic implications [J]. Am J Puthol,1995,147(3): 815-822.
[7]Bartolazzi A, Gasbarri A. Papotti M, et al. Application of an Imuuodiagnostic method for improving preoperative diagnosis of nodular thyriod lesion [J].lancer,2001.357(9269):1664-1650.
[8]孙团起王卓颖等,甲状腺肿块细针穿刺细胞学标本中galectin-3和VEGF-C的检测及其价值[J].中国癌症杂志,200515(6)：527-530.
[9]黄悦,赵建华等HBME-1和CK19、 Galectin-3在甲状腺乳头状癌中表达及诊断价值[J].南京医科大学学报,2007 11(11)：1295-1297.
[10]张晓邱新光,桥本病伴结节样变中Galectin-3, CK19的表达及其临床意义[J].中国实用医刊,2008 35 (12):09-11.
[11]Bondenmuller H, Banauch D. Technical evaluation of a new automated tumor marker assay; the Enzymun-test CYFRA21-1. In： Klapdor R. Tumor associated antigens oncogenes receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90th [M]. Zuckschwerdt Verlag,1992:137-138.
[12]Cheung C C, Ezzat S. Immunohistochemical diagnosis of papillary thyroid carcinoma [J]. Mod Pathol,2001(14):338-342.
[13]Sahoo S, Hoda S A, Rosai J. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma:a note of caution [J]. Am J Clin Pathol,2001,1(16): 696-702.
[14]Metfinen M. Keratin subsets in papillary and fol. licular thyroid lesions:A pammn section analysis with diagnosis implications [J]. VichowsArch,1997:431-407.
[15]Kazantseva IA, Fedosenko AK, Gurevich LE, et al. Immunohistochemicalstudy in differential diagnosis of benign and malignant lesions of the thyroid gland [J]. Arkh Patol,2001 63(4):18-21.
[16]Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction[J]. Cancer research,1994,54(11):2986-2990.
[17]Srivastava S, Banerjee H, Chaudhry, et al. Apoptosis-inducing factor regulates death in peripheral T cells[J]. J Immunol,2007,179(2):797-799.
[18]Prasad ML, Huang Y, Pellegate NS, Hashimoto's thyrioditis with papilly thyroid carcinoma(PTC)-like muclear alterations express molecular of PTC[J]. Histopathology,2004,45(1):39-46.
[19]Di Pasquale M, Rothstein, Palazzo JP. Pathologic features of hashimoto,s associated papillary thyroid carcinomas[J]. Hum Pathol,2001,32(1):24-30.
pathologic study of 354 patients. [J] Clin Endoerinal,1952,12(4):1578-1583.
[2]Cipolla C, Sandonato L, Graceffa G, Hashimoto thyroiditis coexistent with
papillary thyroid carcinoma[J]. Am Surg,2005,71(10):874-878[3]王兰,潘丹.桥本甲状腺炎伴甲状腺癌临床病理分析[J].临床与实验病理学杂志,2003,29(3)：286-289.
[4]Di Pasquale M, Rotjstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carCinoma[J]. Hum Pathol,2001,32 (1); 24-30.
[5]Prasad ML, Huang Y, Pellegate NS, Hashimoto's thyrioditis with papilly thyroid carcinoma(PTC)-like muclear alterations express molecular of PTC[J]. Histopathology,2004,45(1):39-46.
[6]Kim KH, Suh KS, Kang DW, Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyrioditis[J]. Pathol Int,2005,55 (9):540-545.
[7]Intidhar Labidi S, Chaabouni AM, Kraiern T, et al. Thyroid carcinoma and Hashimoto thyroiditis [J].Ann Otolaryngol Chir Cervicofac,2006,123(4):175.
[8]Costanzo M, Caruso LA, Teatar R, et al.Hashimoto thyrioitis possible cause or consequence of a malignant thyroid tumor[J]. Ann Ital Chir,2006,77(6):469.
[9]Arif S. Blanes A. Diaz-Cano SJ. Hashimot*s thyroiditis shares features with early papillaD thyroid dcarcinoma[J]. Histolmthology 2002,41(4):357-62.
[10]Honjo Y, Inohara H, Akahani S, et al. Expression of cyto-plasmic galectin-3 as a prognostic marker in tongue carcinoma[J]. Clin Cancer Res,2000,6(12): 4635-4640.
[11]Xu XC. El-Nagger AK、lotan R. differential expression of galectin-1 and galectin-3 in thyroid tumors:potential diagnostic implications[J]. Am J Puthol.1995,147(3) 815-822.
[12]Rhoden KJ, Unger K, Salvatore G, RET/papillary thyroid cancerr rearrangement in nonneoplastic thyrocytes:follicular cells of Hashimoto's thyrioditis share low-level recombination events with a subset of papillary carcinoma[J]. Clin Endocrinol Metab,2006,91 (6):2040-2042.
[13]Nikiforova M, Caudill C, Biddinger P, et al. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinoma. [J]. Int J Surg Pathol,2002,10(1):15-22.
[14]Unger P, Ewart M, Wang BY, Expression of p63 in papillary thyriod carcinoma and in Hashimoto's thyrioditis:a pathobiologic link [J]. Hum Pathol,2003,34(8):764-769.
[15]徐少明,王平等,桥本氏病并发甲状腺癌的临床分析[J].中华医学杂志,2000,80(4)：278-279.
[16]Gasbarri A, Sciacchitano S, Marasco A, Detectionand molecular characterization of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyrioditis[J].Br J Cancer,2004,91(6):1096-1104.
[17]Bartolazzi A, Gasbarri A. Papotti M, et al. Application of an Imuuodiagnostic method for improving preoperative diagnosis of nodular thyriod lesion
[J]. lancer.2001.357(9269):1664-1650.
[18]王兰,潘丹等,桥本氏甲状腺炎伴甲状腺癌的临床病理分析[J].临床与实验病理学杂志.2003 19(3)：286-289.
[19]Rosai J, Zampi G. Papillary carcinoma of the thy. mid, a discussion of its several morphologic expressions, thpanicukr emphasis on the follicular variant [J]. Am J Surg Pathol,1983,7:809-817.
[20]Sahoo S, Hoda S A, Rosai J. Cytokeratin 19 immunoreactivity in the diagnosis
of papillary thyroid carcinoma:a note of caution [J]. Am J Cl in Pathol,2001,116: 696-702.
[21]Metfinen M. Keratin subsets in papillary and fol. licular thyroid lesions:A pammn section analysis with diagnosis implications[J]. Vichows Arch,1997,431: 407.
[22]贾万钧郭艳, CK19、 galectin-3、 HBME-1和Ret蛋白在甲状腺乳头状癌中的表达[J]浙江临床医学2007 11(9)：1143-1144.
[23]王仪,魏霖等,Galectin-3、 CK19和MC在甲状腺良、恶性肿瘤中的表达及意义[J]海峡药学2007 19(12)：108-110.
[24]Kazantseva IA, Fedosenko AK, Gurevich LE, et al. Immunohistochemicalstudy in differential diagnosis of benign and malignant lesions of the thyroid gland[J]. Arkh Patol,2001,63(4):18-21.
[25]王家耀.桥本甲状腺炎与甲状腺癌的关系[J].诊断病理学杂志,1997；4(2)：106-107.
[26]戴军,陈方荟,包建东,等.桥本甲状腺炎癌变与甲状腺乳头状癌相关性分析[J].诊断病理学杂志.2005,12(6)：458-459.
[27]Di Pasquale M, Rothstein, Palazzo JP. Pathologic features of hashimoto' sassociated papillary thyroid carcinomas[J]. Hum Pathol,2001,32(1):24-30.
[28].Dayan CM, Danniels GH. Chronic autoimmune thyroiditis. New Engl [J] Med,1996;335(2):99-110.
[29]Vanderpump MPJ, Tumbridge WMC, French JM, et al. The incidence of thyroiditis:the great mimic. Nucl Med Commun;1988; 9(9):639-645.
[30]Crile G Jr. Controversies in thyroid surgery. N Y Stste J Med.1980 Nov; 80 (12) 1832-1835
[31]Martin HE, Ellis EB. Biopsy by needle puncture and aspiration. Ann surg,1930, (92):169-181.
[32]Cattell RB. Postoperation complications of thyroid surgery. Surg Clin North AM.1953 Jun:867-877.
[33]Foot NC, Baker LE, Carrel A. The behavior of abnormal human thyroid tissue cultivated in the Lindbergh apparatus. J Exp med.1939 Jun 30:70(1)39-52.
[34].李里等,桥本病合并甲状腺肿瘤的外科治疗和临床特征分析[J]中国癌症杂志.2009，19(7)：544-547.
[1]Lindsay S, Dailey ME, Eriedlender J, et al. Chronic throiditis:a clinical and pathologic study of 354 patients[J]. Clin Endoerinal,1952,12(4):1 578-1 583.
[2]顾学文,张真稳等Galectin-3、 Cytokeratin-19在甲状腺良恶性乳头状病变中的表达及临床意义[J].实用医学杂志,2005 21(12)：1125-1126.
[3]郑璐滢,朱建善等Galectin-3、 CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J]临床与实验病理学杂志[J]. Clin Exp Pathol.2005 Aug; 20(4):449-452.
[4]Honjo Y, Inohara H, Akahani S, et al. Expression of cyto-plasmic galectin-3 as a prognostic marker in tongue carcinoma[J].Clin Cancer Res,2000,6(12): 4635-4640.
[5]Ohannesian DW, Lotan D, Thomas, et al. Carcinoembryonic antigen and other glycoconiugates act as ligands for galeetin-3 in human colon carcinoma cells [J]. Cancer Res,1995,55(10):2191-2199.
[6]Xu XC, El-Nagger AK, lotan R. differential expression of galectin-1 and galectin-3 in thyroid tumors:potential diagnostic implications [J]. Am J Puthol,1995,147(3): 815-822.
[7]Bartolazzi A, Gasbarri A. Papotti M, et al. Application of an Imuuodiagnostic method for improving preoperative diagnosis of nodular thyriod lesion [J].lancer,2001.357(9269):1664-1650.
[8]孙团起王卓颖等,甲状腺肿块细针穿刺细胞学标本中galectin-3和VEGF-C的检测及其价值[J].中国癌症杂志,200515(6)：527-530.
[9]黄悦,赵建华等HBME-1和CK19、 Galectin-3在甲状腺乳头状癌中表达及诊断价值[J].南京医科大学学报,2007 11(11)：1295-1297.
[10]张晓邱新光,桥本病伴结节样变中Galectin-3, CK19的表达及其临床意义[J].中国实用医刊,2008 35 (12):09-11.
[11]Bondenmuller H, Banauch D. Technical evaluation of a new automated tumor marker assay; the Enzymun-test CYFRA21-1. In： Klapdor R. Tumor associated antigens oncogenes receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90th [M]. Zuckschwerdt Verlag,1992:137-138.
[12]Cheung C C, Ezzat S. Immunohistochemical diagnosis of papillary thyroid carcinoma [J]. Mod Pathol,2001(14):338-342.
[13]Sahoo S, Hoda S A, Rosai J. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma:a note of caution [J]. Am J Clin Pathol,2001,1(16): 696-702.
[14]Metfinen M. Keratin subsets in papillary and fol. licular thyroid lesions:A pammn section analysis with diagnosis implications [J]. VichowsArch,1997:431-407.
[15]Kazantseva IA, Fedosenko AK, Gurevich LE, et al. Immunohistochemicalstudy in differential diagnosis of benign and malignant lesions of the thyroid gland [J]. Arkh Patol,2001 63(4):18-21.
[16]Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction[J]. Cancer research,1994,54(11):2986-2990.
[17]Srivastava S, Banerjee H, Chaudhry, et al. Apoptosis-inducing factor regulates death in peripheral T cells[J]. J Immunol,2007,179(2):797-799.
[18]Prasad ML, Huang Y, Pellegate NS, Hashimoto's thyrioditis with papilly thyroid carcinoma(PTC)-like muclear alterations express molecular of PTC[J]. Histopathology,2004,45(1):39-46.
[19]Di Pasquale M, Rothstein, Palazzo JP. Pathologic features of hashimoto,s associated papillary thyroid carcinomas[J]. Hum Pathol,2001,32(1):24-30.